Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed May 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$949K
Net Open-Market Flow
-$949K
Transactions
7
6 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 6, 2026Option exercise(M)47K$8.04$378K47K
May 6, 2026Sell(S)14K$18.55$257K34K
May 6, 2026Sell(S)12K$19.28$238K21K
May 6, 2026Sell(S)3K$20.76$56K19K
May 6, 2026Sell(S)9K$21.37$197K9K
May 6, 2026Sell(S)9K$22.57$201K423

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 6, 2026Option exercise(M)47K$0116K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000010) within minutes of acceptance. Every field above traces to the original document. Verify it directly: